NCT01626859View on ClinicalTrials.gov

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Schizophrenia
Interventions
DRUG

MP-214 3mg

Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.

DRUG

MP-214 6mg

Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.

DRUG

MP-214 9mg

Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.

Trial Locations (1)

Unknown

Sakai

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY